285 related articles for article (PubMed ID: 16702472)
1. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative.
Hendrix SL; Wassertheil-Smoller S; Johnson KC; Howard BV; Kooperberg C; Rossouw JE; Trevisan M; Aragaki A; Baird AE; Bray PF; Buring JE; Criqui MH; Herrington D; Lynch JK; Rapp SR; Torner J;
Circulation; 2006 May; 113(20):2425-34. PubMed ID: 16702472
[TBL] [Abstract][Full Text] [Related]
2. Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the women's health initiative randomized trial.
Jackson RD; Wactawski-Wende J; LaCroix AZ; Pettinger M; Yood RA; Watts NB; Robbins JA; Lewis CE; Beresford SA; Ko MG; Naughton MJ; Satterfield S; Bassford T;
J Bone Miner Res; 2006 Jun; 21(6):817-28. PubMed ID: 16753012
[TBL] [Abstract][Full Text] [Related]
3. Menopause and stroke and the effects of hormonal therapy.
Lobo RA
Climacteric; 2007 Oct; 10 Suppl 2():27-31. PubMed ID: 17882669
[TBL] [Abstract][Full Text] [Related]
4. Effects of conjugated equine estrogen on health-related quality of life in postmenopausal women with hysterectomy: results from the Women's Health Initiative Randomized Clinical Trial.
Brunner RL; Gass M; Aragaki A; Hays J; Granek I; Woods N; Mason E; Brzyski R; Ockene J; Assaf A; LaCroix A; Matthews K; Wallace R;
Arch Intern Med; 2005 Sep; 165(17):1976-86. PubMed ID: 16186467
[TBL] [Abstract][Full Text] [Related]
5. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative.
Hsia J; Langer RD; Manson JE; Kuller L; Johnson KC; Hendrix SL; Pettinger M; Heckbert SR; Greep N; Crawford S; Eaton CB; Kostis JB; Caralis P; Prentice R;
Arch Intern Med; 2006 Feb; 166(3):357-65. PubMed ID: 16476878
[TBL] [Abstract][Full Text] [Related]
6. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial.
Anderson GL; Limacher M; Assaf AR; Bassford T; Beresford SA; Black H; Bonds D; Brunner R; Brzyski R; Caan B; Chlebowski R; Curb D; Gass M; Hays J; Heiss G; Hendrix S; Howard BV; Hsia J; Hubbell A; Jackson R; Johnson KC; Judd H; Kotchen JM; Kuller L; LaCroix AZ; Lane D; Langer RD; Lasser N; Lewis CE; Manson J; Margolis K; Ockene J; O'Sullivan MJ; Phillips L; Prentice RL; Ritenbaugh C; Robbins J; Rossouw JE; Sarto G; Stefanick ML; Van Horn L; Wactawski-Wende J; Wallace R; Wassertheil-Smoller S;
JAMA; 2004 Apr; 291(14):1701-12. PubMed ID: 15082697
[TBL] [Abstract][Full Text] [Related]
7. Conjugated equine estrogen and risk of benign proliferative breast disease: a randomized controlled trial.
Rohan TE; Negassa A; Chlebowski RT; Habel L; McTiernan A; Ginsberg M; Wassertheil-Smoller S; Page DL
J Natl Cancer Inst; 2008 Apr; 100(8):563-71. PubMed ID: 18398105
[TBL] [Abstract][Full Text] [Related]
8. Conjugated equine estrogens and peripheral arterial disease risk: the Women's Health Initiative.
Hsia J; Criqui MH; Herrington DM; Manson JE; Wu L; Heckbert SR; Allison M; McDermott MM; Robinson J; Masaki K;
Am Heart J; 2006 Jul; 152(1):170-6. PubMed ID: 16824852
[TBL] [Abstract][Full Text] [Related]
9. The effect of medroxyprogesterone acetate on estrogen-dependent risks and benefits--an attempt to interpret the Women's Health Initiative results.
Kuhl H; Stevenson J
Gynecol Endocrinol; 2006 Jun; 22(6):303-17. PubMed ID: 16785155
[TBL] [Abstract][Full Text] [Related]
10. Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative.
Barnabei VM; Cochrane BB; Aragaki AK; Nygaard I; Williams RS; McGovern PG; Young RL; Wells EC; O'Sullivan MJ; Chen B; Schenken R; Johnson SR;
Obstet Gynecol; 2005 May; 105(5 Pt 1):1063-73. PubMed ID: 15863546
[TBL] [Abstract][Full Text] [Related]
11. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial.
Wassertheil-Smoller S; Hendrix SL; Limacher M; Heiss G; Kooperberg C; Baird A; Kotchen T; Curb JD; Black H; Rossouw JE; Aragaki A; Safford M; Stein E; Laowattana S; Mysiw WJ;
JAMA; 2003 May; 289(20):2673-84. PubMed ID: 12771114
[TBL] [Abstract][Full Text] [Related]
12. Post-menopausal hormone replacement therapy (cont'd): risk-benefit balance in the hot seat.
Prescrire Int; 2004 Jun; 13(71):106-9. PubMed ID: 15233153
[TBL] [Abstract][Full Text] [Related]
13. Estrogen plus progestin and the risk of peripheral arterial disease: the Women's Health Initiative.
Hsia J; Criqui MH; Rodabough RJ; Langer RD; Resnick HE; Phillips LS; Allison M; Bonds DE; Masaki K; Caralis P; Kotchen JM;
Circulation; 2004 Feb; 109(5):620-6. PubMed ID: 14769684
[TBL] [Abstract][Full Text] [Related]
14. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin.
Anderson GL; Chlebowski RT; Rossouw JE; Rodabough RJ; McTiernan A; Margolis KL; Aggerwal A; David Curb J; Hendrix SL; Allan Hubbell F; Khandekar J; Lane DS; Lasser N; Lopez AM; Potter J; Ritenbaugh C
Maturitas; 2006 Sep; 55(2):103-15. PubMed ID: 16815651
[TBL] [Abstract][Full Text] [Related]
15. New evidence regarding hormone replacement therapies is urgently required transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits.
Modena MG; Sismondi P; Mueck AO; Kuttenn F; Lignières Bd; Verhaeghe J; Foidart JM; Caufriez A; Genazzani AR;
Maturitas; 2005 Sep; 52(1):1-10. PubMed ID: 15963666
[TBL] [Abstract][Full Text] [Related]
16. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials.
Manson JE; Chlebowski RT; Stefanick ML; Aragaki AK; Rossouw JE; Prentice RL; Anderson G; Howard BV; Thomson CA; LaCroix AZ; Wactawski-Wende J; Jackson RD; Limacher M; Margolis KL; Wassertheil-Smoller S; Beresford SA; Cauley JA; Eaton CB; Gass M; Hsia J; Johnson KC; Kooperberg C; Kuller LH; Lewis CE; Liu S; Martin LW; Ockene JK; O'Sullivan MJ; Powell LH; Simon MS; Van Horn L; Vitolins MZ; Wallace RB
JAMA; 2013 Oct; 310(13):1353-68. PubMed ID: 24084921
[TBL] [Abstract][Full Text] [Related]
17. A comparative review of the risks and benefits of hormone replacement therapy regimens.
Warren MP
Am J Obstet Gynecol; 2004 Apr; 190(4):1141-67. PubMed ID: 15118656
[TBL] [Abstract][Full Text] [Related]
18. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial.
LaCroix AZ; Chlebowski RT; Manson JE; Aragaki AK; Johnson KC; Martin L; Margolis KL; Stefanick ML; Brzyski R; Curb JD; Howard BV; Lewis CE; Wactawski-Wende J;
JAMA; 2011 Apr; 305(13):1305-14. PubMed ID: 21467283
[TBL] [Abstract][Full Text] [Related]
19. The effect of tibolone and continuous combined conjugated equine oestrogens plus medroxyprogesterone acetate on progression of carotid intima-media thickness: the Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) study.
Bots ML; Evans GW; Riley W; McBride KH; Paskett ED; Helmond FA; Grobbee DE;
Eur Heart J; 2006 Mar; 27(6):746-55. PubMed ID: 16415304
[TBL] [Abstract][Full Text] [Related]
20. Results from the Estonian postmenopausal hormone therapy trial [ISRCTN35338757].
Veerus P; Hovi SL; Fischer K; Rahu M; Hakama M; Hemminki E
Maturitas; 2006 Sep; 55(2):162-73. PubMed ID: 16504428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
